within Pharmacolibrary.Drugs.ATC.A;

model A04AD01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.05e-05,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0044,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0089,
    k12             = 0.71,
    k21             = 0.71
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Scopolamine (also known as hyoscine) is a tropane alkaloid with antimuscarinic properties, primarily used to prevent nausea and vomiting associated with motion sickness and postoperative recovery. It is FDA-approved and commonly administered as a transdermal patch or parenterally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from healthy adult volunteers, after intravenous (IV) administration.</p><h4>References</h4><ol><li><p>Renner, UD, et al., &amp; Kirch, W (2005). Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. <i>Therapeutic drug monitoring</i> 27(5) 655–665. DOI:<a href=\"https://doi.org/10.1097/01.ftd.0000168293.48226.57\">10.1097/01.ftd.0000168293.48226.57</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16175141/\">https://pubmed.ncbi.nlm.nih.gov/16175141</a></p></li><li><p>Putcha, L, et al., &amp; Kramer, WG (1989). Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. <i>Pharmaceutical research</i> 6(6) 481–485. DOI:<a href=\"https://doi.org/10.1023/a:1015916423156\">10.1023/a:1015916423156</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2762223/\">https://pubmed.ncbi.nlm.nih.gov/2762223</a></p></li><li><p>Nachum, Z, et al., &amp; Gordon, CR (2006). Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 45(6) 543–566. DOI:<a href=\"https://doi.org/10.2165/00003088-200645060-00001\">10.2165/00003088-200645060-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16719539/\">https://pubmed.ncbi.nlm.nih.gov/16719539</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AD01;
